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Development of Orally Dissolving Films for Pediatric-Centric Administration 
of Anti-Epileptic Drug Topiramate – a Design of Experiments (DoE) Study
Abstract: Children have often been treated as small adults in relation to drug formulation, but 
research has now shown this not to be the case. Therefore, there is a push from regulatory bodies 
to provide drug formulations specifically tailored towards the needs of this fragmented population. 
Orally dissolving films (ODFs) have been identified as an emerging opportunity, to bridge this 
gap. Therefore, the aim of this study was to prepare ODFs containing topiramate, an antiepileptic 
drug, using solvent casting method as a potential alternative to oral tablets/powders for paediatrics. 
For this purpose, a Design of Experiment (DoE) was employed to optimise formulation 
parameters. 24 formulations were prepared by changing the polymer type (HPMC, Guar-Gum or 
PEO), concentration (0.4%-1.2%w/v); plasticizer type (glycerol\sorbitol) and concentration (0.1-
0.3%w/v). Disintegration time, content-uniformity, film quality and thickness uniformity were the 
responses. Surface and molecular profiling were conducted on the optimal formulation (N4). TGA 
and XRD results demonstrated the stability of materials upon production into films, while the SEM 
images showed smooth films that proved to be resilient due to good mechanical properties. HPMC-
glycerine based ODFs are presented as an effective dosage form to enhance the ease of 
administration and patient compliance of topiramate, specifically for paediatric patients. 
Keywords: Orally dissolving films; Drug load; Pediatric formulations; Topiramate; Solvent 
casting; Design of experiment (DoE).
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1. Introduction 
The European Medicines Agency (EMA) has recognised the need for legal guidance for the 
development of medicines for paediatric use, since medications intended for paediatric patients 
have a number of challenges associated with them. These challenges are pertinent to dose 
flexibility, high load efficiency of above 30%, dose accuracy, overcoming dysphagia and 
developing user friendly dosage forms; which are capable of meeting the needs of a population 
with diverse physiological characteristics and levels of maturity; and to ensure patient adherence 
(such as with taste masking) (Ivanovska et al., 2014).
Children differ from adults in relation to pharmacotherapy, including capabilities for drug 
administration, drugs toxicity, and taste preferences. A focus on novel preparations is required 
particularly upon the changes in regulations in 2007. Where it became important that paediatric 
drugs be formulated to best suit a child’s age, size, physiological condition, and treatment 
requirements. To ensure suitable treatment of all children, different routes of administration, 
dosage forms, and strengths may be required. Many formulations are not suitable for children, 
therefore, the selection of an all encompassing paediatric dosage form is challenging (Hanning et 
al., 2016; Lopez et al., 2015). One of the challenges stem from the use of inactive ingredients 
(excipients) which although generally regarded as safe (GRAS) in adults, have not been validated 
for pediatric use. Some excipients commonly used in adult medicines showed elevated toxicity 
and safety issues in children, especially neonates (Cuzzolin, 2018; Ivanovska et al., 2014; Turner 
et al., 2014). Therefore paediatric drug formulation development is associated with numerous 
challenges, including methodologic and ethical requirements for pediatric trials, high 
developmental costs, and a small and fragmented market. As a result of these challenges, there 
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have only been limited research efforts to adapt medicines according to paediatric needs 
(Ivanovska et al., 2014).
Orally dissolving films (ODFs) are a type of oral drug delivery system that was developed based 
on transdermal patch technology. This delivery system consists of a thin film, which is simply 
placed on the patient’s tongue or mucosal tissue, instantly gets wetted by saliva, then rapidly 
disintegrates and dissolves to release the medication for oral mucosal absorption. This fast 
dissolving action is primarily due to the large surface area of the film, which wets quickly when 
exposed to oral moisture. ODFs, extensively reviewed in literature,  improve the efficacy of the 
active pharmaceutical ingredient (API) by dissolving in short duration in the oral cavity after 
contact with less amount of saliva as compared to dissolving tablets (Abay and Ugurlu, 2015; Ouda 
et al., 2020; Saab and Mehanna, 2019; Thakur et al., 2013). ODFs offer several advantages such 
as ease of management for pediatrics, they do not require water for swallowing – a very convenient 
feature for patients who travel. They possess a good mouth feel and therefore help to change the 
perception of the medicine as a bitter medicine, especially for paediatric patients. Some drugs may 
be absorbed from the mouth, pharynx and oesophagus as the saliva passes down into the stomach, 
which enhances bioavailability of drugs. This pre-gastric absorption can lead to improved 
bioavailability resulting in dose reduction. The risk of suffocation or choking during oral 
administration of conventional solid formulations due to physical obstruction is avoided, thus 
providing improved safety. ODFs are useful in cases where a rapid onset of action is required. 
ODFs demonstrate stability for longer periods of time, since the drug remains in solid state until it 
is consumed. Therefore, ODFs combine the advantages of solid dosage forms in terms of stability 
and liquid dosage forms in terms of bioavailability (Ouda et al., 2020; Patil and Shrivastava, 2014; 
Saab and Mehanna, 2019).
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Epilepsy is a relatively common condition in children, where its prevalence is approximately 
3.2 – 5.5 per 1000 children in the developed world. It has been estimated that 12 – 39% of children 
with epilepsy also have some form of attention deficit hyperactivity disorder (ADHD) (Curatolo 
et al., 2017). Topiramate (TPM) was approved for treatment of epilepsy in the US in 1995. It is a 
sulfamate substituted monosaccharide with a novel combination of pharmacological properties. 
Pharmacokinetically, TPM shows many desirable characteristics such as rapid absorption, minimal 
binding to plasma proteins, no enzymatic auto induction and linear kinetics. However, its 
metabolism is induced by phenytoin and carbamazepine. Hence, concomitant administration of 
these antiepileptic drugs accelerates TPM elimination rate and decreases its plasma concentration 
by 50% (Pellock and Watemberg, 1997). Topiramate use in pediatrics has been established, where 
it is effective and well tolerated in children under the age of 12 years in many epileptic conditions, 
including refractory partial epilepsy and symptomatic and myoclonic generalized epilepsy 
(Mikaeloff et al., 2003). Topiramate is a crystalline solid with melting point of 125-126 °C, water 
solubility reaching 9.8 mg/mL,  with bitter taste. The saturated solution has a pH of 6.3 (PubChem, 
2019). According to the biopharmaceutical classification system (BCS), topiramate is classified as 
Class I drug (high solubility and high permeability at the maximum dose) (EMA, 2013; Talati et 
al., 2012). It has a recommended therapeutic dose of 25 mg once or twice daily for children 6 – 17 
years old, and can go higher according to the classification and severity of the condition (Mikaeloff 
et al., 2003). The currently available paediatric dosage form is based on capsules that are opened 
and sprinkled on soft food then swallowed (BNF, 2017). Therefore, the provision of topiramate as 
ODFs may provide a more convenient dosage form for patients. 
Based on the foregoing, the aim of this work was to develop and characterise paediatric-centric 
orally disintegrating film formulations containing 25mg TPM per film, as a novel, safe and 
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acceptable dosage forms for treatment of epilepsy in children using design of experiments (DoE) 
mathematical approach. Different polymers (Hydroxypropyl methyl cellulose, guar gum, 
polyethylene oxide) and plasticizers (glycerine or sorbitol) were used over a range of 
concentrations. 
2. Materials and Methods 
2.1. Materials 
Topiramate, hydroxypropyl methyl cellulose K100 (HPMC), guar gum (GG), polyethylene 
oxide (molecular weight 100,000 Da) (PEO) glycerine, sorbitol, potassium dihydrogen phosphate, 
and ethanol (absolute HPLC grade) were purchased from Sigma Aldrich (Pool, UK). Disodium 
hydrogen phosphate, sodium chloride and phosphoric acid were purchased from AZ Chemicals, 
Inc. (ON, Canada). Distilled water was used in all experiments. All chemicals were used as 
received. 
2.2. Methods 
2.2.1 Preparation of topiramate loaded orally dissolving films 
The topiramate loaded ODFs were prepared using solvent casting method according to the method 
described by (Ouda et al., 2020). Initially, the accurately weighed film-forming polymer (HPMC, 
PEO or GG) was dissolved in 50 ml distilled water at temperature of 35 - 40 ℃ using a hotplate-
magnetic stirrer (Dragonlab- MS-H-S, China), stirred at 1250 rpm, and then allowed to stand for 
2 h for swelling and complete hydration. Then, the plasticizer (glycerine or sorbitol) was added to 
the polymer solution and stirred at 1250 rpm and 40 ℃ to obtain a homogenous solution. The 
polymeric solution was kept for 45-60 minutes in an ultrasonic bath [(Sonorex Digitec 
(BANDELIN electronics, GmbH)] set at medium speed to enable the removal of bubbles. Next, 
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an accurately weight of topiramate powder was added to 40 ml of distilled water and stirred on 
magnetic stirrer at 1000 rpm till complete dissolution.  The topiramate solution was then added 
slowly to the polymeric solution and stirred to form a homogenous solution. The final volume was 
adjusted to 100 ml with distilled water, then was degassed using the ultrasonic bath. After 
degassing, the solution was casted on plastic Petri dishes (25 ml per dish) and dried at room 
temperature for 24 hrs, to avoid quick drying and film deformation, then in an oven at 40 ℃ for 10 
hrs. The films were carefully removed from the surface and cut into the rectangles of 3×2 cm2 per 
film. The films were stored in a dry place for further analysis. Results of our previous work (Ouda 
et al., 2020) employing different polymers and plasticizers showed successful films with polymer 
concentration around 0.6-1% and plasticizer concentration of 0.1-0.2%. This study aimed at 
optimizing the polymer and plasticizer types and concentrations, therefore, the employed polymer 
concentrations were 0.4%, 0.8% or 1.2%w/v. The plasticizer concentrations were 0.1%, 0.2% and 
0.3% w/v. Table 1 summarizes the concentrations used in this study.    
Table 1 [near here]
2.2.2 Design of Experiment (DoE) 
The statistical analytical technique was performed using MODDE software version 12.1 
(Umetrics Inc., Sweden). D-optimal design for the DoE with quadratic model was selected, 
which was further fitted using partial least squares (PLS) method. Whereas response surface 
modelling (RSM) was employed to investigate and optimize the non-linear multidimensional 
relationship between factors and responses. A total of 24 experiments were produced, that 
include triplicate runs to evaluate the repeatability and error estimation. To fit the quadratic 
model. The experiments were conducted depending on proposed run order which was given by 
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the software; so, the randomness of the process could be assessed. Table 2 specifies the factors 
and responses which were used in the DoE, respectively.
Table 2 [near here]
In the design, none of the factors or responses underwent transformation of values and 
hence the type was regular. However, various proportions of the polymer concentration and 
plasticizer concentration were encoded in the D-optimal design as -1, 0 or 1 that stand for the 
lowest value, intermediate value, and the highest value respectively. Table 3 summarizes the D-
optimal design worksheet with the proportions of factors, the total number of runs as well as the 
run order.
Table 3 [near here]
2.2.3 UV-VIS spectrophotometric assay method for topiramate
The amount of topiramate loaded in, or released from, the ODFs was quantified using a UV-
VIS spectrophotometer method. Maximum wavelength of topiramate was determined using 
Thermo Fisher Scientific Double Beam UV-VIS Spectrophotometer with maximum detected at 
264 nm.  50 mg of topiramate was accurately weighed, transferred into a 100 ml volumetric flask. 
The final volume was adjusted to 100 ml with ethanol (for content uniformity studies) or water 
(for the dissolution study). Serial dilutions were made from the solution using ethanol or water  to 
obtain the following concentrations: 500 μg/ml, 250 μg/ml, 125 μg/ml, 62.5 μg/ml, and 31.25 
μg/ml, 15.625 μg/ml. Samples were analyzed using UV- VIS spectrophotometer at 264 nm using 
ethanol as blank. Experiments were performed in triplicate and repeated three times on consecutive 
days. The data were plotted as absorbance verses concentration and regression coefficient was 
calculated from the straight-line equation. The method was validated  according to the 
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International Conference on Harmonization (ICH) guidelines (Validation of Analytical Procedures 
Q2(R1)) in terms of specificity, accuracy, precision, linearity and  limit of detection/quantification 
(ICH, 2005). Linearity was over a range of 0-125 µg/ml (for water and ethanol), LOD and LOQ  
were 3.00 µg/ml and 9.09 µg/ml respectively for ethanol based data and 3.76 µg/ml and 11.02 
µg/ml for water based data respectively.  None of the excipients interfered with the absorbance at the 
used higher concentrations. 
2.2.4 Preparation of artificial saliva 
The artificial saliva solution was prepared according to the method in (Ouda et al., 2020).  To 
prepare a litre of artificial saliva 2.382 g of di-sodium hydrogen phosphate was dissolved in 500 
ml distilled water. Then 0.190 g of potassium dihydrogen phosphate (0.019%) and 8 g of sodium 
chloride (0.8%) were added to form a homogenous saliva solution. The final volume was adjusted 
to 1 L using distilled water. The pH of the solution was further adjusted to 6.75 with phosphoric 
acid and was used as test medium for disintegration.
2.2.5 Characterization of the ODFs
The prepared ODFs for all the produced formulations N1-N24 were characterized using 
various techniques including disintegration time, content uniformity, film quality, and thickness 
uniformity. Selected formulations that demonstrated good properties were further analysed using 
in-vitro dissolution profile, SEM, mechanical properties, XRD, and TGA. 
Film quality. 
The quality of the produced films was assessed based on 5 criteria. Each criterion was given 
20% of the total value. The criteria include 1) film flexibility (endurance > 30 times), 2) good 
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spreadability upon pouring onto the casting tray, 3) not sticky film, 4) easy to peel off casting tray, 
and 5) smooth appearance. Table 4 summarise the scoring criteria.
Table 4 near here
Disintegration time. 
Disintegration test was performed based on our previously reported method (Ouda et al., 
2020). Since there is no specific time limit for rapidly dissolving ODFs in compendial references, 
the orally dissolving time frame was employed to assess ODFs (Ph.Eur, 2010; Saab and Mehanna, 
2019).  The 180 seconds limit identified by European Pharmacopeia was employed with a set target 
of 60 seconds. The film was placed in a beaker containing 10 mL of artificial salvia (pH 6.75). To 
simulate in vivo conditions the test was performed in 10 ml of artificial saliva. The ODF was 
placed horizontally in a 30 ml beaker with 10 ml of artificial salvia media. The beaker was placed 
in a larger beaker containing 100 ml distilled water, and the temperature was maintained at 37 ºC 
using hot plate. Magnetic stirrer was used set at 10 rpm.  All studies were performed in triplicate 
for each formulation. The disintegration time was determined when the film dissolved or 
fragmented into small pieces.
Content uniformity. 
One ODF was dissolved in ethanol and volume completed to 50 mL ethanol. The solution was 
sonicated without heat for 10 minutes to ensure complete dissolution of the active ingredient. From 
this solution, 1 mL was diluted with 1 mL of ethanol, then the sample was filtered using syringe 
filter (0.45 µm), then the absorbance was measured using a UV spectrophotometer at 264 nm for 
topiramate using ethanol as blank. Experiments were performed in triplicate for each formulation 
and the average values were recorded. 
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Thickness uniformity. 
The uniformity of thickness for the ODFs was carried out using 3 films per formulation. Each
film (3×2 cm) was taken randomly, and the thickness was measured from five locations (4 corners 
and the centre) using Kendo digital calliper (Shanghai, China). The mean and relative standard 
deviation (RSD) were calculated, and RSD reported.
Thermogravimetric analysis (TGA). 
The TG curves were obtained using a Thermogravimetric Analyser Pyris 1 TGA instrument, 
(Perkin Elmer, USA). Pyris manager software was used to analyse the results. A sample mass 5 to 
10 mg was used in the test. Samples were held for 2 minutes at 25 ℃ then measurements were 
obtained from 25 to 800 ℃ under nitrogen atmosphere. The heating rate was set at 10 ℃/min.
Scanning electron microscope (SEM). 
SEM images were obtained using a JSM-IT300 (Manufacture JEOL, JAPAN). A 2x2 mm piece 
of the film was mounted on a double adhesive carbon tape placed on an aluminium tub. Samples 
were analysed at low vacuum without further coating. 
X-ray diffraction (XRD). 
X-ray diffractions were obtained for targeted ODF sample using X-ray diffractometer (D8 Phaser, 
Bruker AXS GmbH, Germany). The X-ray generator was operated at 30 kV and 10 mA employing 
Co tube at λ 1.79026 Å as a radiation source and using LYNXEYE detector. The angular range 
(2θ) varied from 4 to 50° at a scanning rate of 0.02° 2θ s-1 and measured at 0.24 second/step.  The 
diffraction patterns were produced as counts per step which were analysed using Topas software 
(Bruker, AXS). 
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Mechanical properties. 
The mechanical properties of the ODFs were evaluated using Instron universal testing machine 
(Instron, USA), with load cell 50N. Films with size 3x2 cm2 were attached on two clamps at the 
distance at 30 mm. These films were pulled by two clamps at rate of 50 mm/min. The parameters 
of mechanical properties including tensile strength and % elongation were assessed. Three samples 
per batch were used and results are reported as mean ± SD. Tensile strength was measured using 
the equation 1 (Ouda et al., 2020): 
 𝑻𝒆𝒏𝒔𝒊𝒍𝒆 𝒔𝒕𝒓𝒆𝒏𝒈𝒕𝒉 (𝑴𝑷𝒂) = ( 𝑳𝒐𝒂𝒅 𝒂𝒕 𝒇𝒂𝒊𝒍𝒖𝒓𝒆𝑭𝒊𝒍𝒎 𝒕𝒉𝒊𝒄𝒌𝒏𝒆𝒔𝒔 × 𝒇𝒊𝒍𝒎 𝒘𝒊𝒅𝒕𝒉) × 𝟏𝟎𝟎……𝑬𝒒.𝟏
Whereas % elongation was determined by the following equation (Eq. 2):  
𝑷𝒆𝒓𝒄𝒆𝒏𝒕𝒂𝒈𝒆 𝑬𝒍𝒐𝒏𝒈𝒂𝒕𝒊𝒐𝒏 (%) =
𝑪𝒉𝒂𝒏𝒈𝒆 𝒊𝒏 𝑳𝒆𝒏𝒈𝒕𝒉
𝑰𝒏𝒊𝒕𝒊𝒂𝒍 𝑳𝒆𝒏𝒈𝒕𝒉 × 𝟏𝟎𝟎…………………..𝑬𝒒. 𝟐
In vitro dissolution studies.  
The release profile of a selected ODF formulation was conducted using the USP type II 
(paddle) dissolution apparatus with distilled water that was maintained at 37 ± 0.5 ℃. The 
dissolution medium was stirred at 100 rpm. 5 ml samples were taken at 5 min interval for 30 
minutes. Distilled water was added to replace the withdrawn samples. Amount of topiramate was 
determined by UV spectrophotometer after filtration using syringe filters (0.45 µm). The percent 
drug released was plotted against time. Results are reported in triplicates with mean and standard 
deviation.
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2.2.6 Statistical analysis 
All data generated in replicates were analysed and presented as mean and standard deviation (SD) 
or relative standard deviation (RSD) using Minitab v. 18. Level of significance was quoted as 
p<0.05, with a confidence interval of 95%. 
3. Results and Discussion 
3.1 Design of Experiment (DoE) 
The aim of this work was to optimize formulation parameters for the development of orally 
dissolving films (ODFs) containing topiramate. Theoretically, a successful film should establish 
excellent content uniformity, exhibit adequate mechanical strength and integrity, and provide fast 
disintegration upon hydration. Good mechanical strength and film integrity can be controlled by 
increasing the polymer concentration, which will increase the film thickness, and optimizing the 
plasticizer concentration, whereas the disintegration time is affected by the film thickness and the 
ratio of polymer concentration to other components. Therefore, critical responses selected as 
dependent variables (responses) were disintegration time, film thickness uniformity, content 
uniformity and film quality.   
HPMC, GG, and PEO were selected as film forming polymers which should give shape and 
provide mechanical strength to the ODF. Moreover, the polymers are hydrophilic which will 
enable quick hydration upon contact with saliva and hence dissolution / disintegration of the thin 
films (Ouda et al., 2020).  The use of plasticizer would enhance the elasticity and flexibility of the 
films (Ding et al., 2015; Irfan et al., 2016). Our previous studies (Ouda et al., 2020) showed that 
HPMC within a concentration range of 0.5-1% is capable of producing good film and that GG with 
insoluble drug produced films with poor coalescence, poor flexibility and difficult to peel off the 
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casting tray. Accordingly, the influence of varying the polymer and plasticizer type (independent 
variables - factors) at three concentration levels on the dependent variables (responses) was 
investigated using the RSM model.
D-optimal model was selected based on the software preference as the most effective and 
efficacious that would enable the prediction of best model. The model was comprised of 24 
experiments in total that entailed 3 replicated centre points. The formulations were developed 
according to the software proposed run order to avoid bias. The films were prepared and evaluated 
for disintegration time, content uniformity, film quality and thickness uniformity and are results 
depicted in Table 3. 
The results in Table 3 revealed that the disintegration time of the ODFs varied from 10 to 
90 s, the film quality from 10%-100%, content uniformity from 82%-108.1%, and thickness 
uniformity from 1.03% to 9.45%. Further, it was noted that all films prepared from GG resulted in 
poor quality in terms of roughness, not easy to peel off casting surface and elasticity. This results 
are in line with our previously reported data (Ouda et al., 2020). Even with the increase in 
plasticizer concentration, the films were marked as poor. Furthermore, in general, HPMC showed 
better results in terms of disintegration time while maintaining better film quality. Low 
concentration of PEO produced films with favourably low disintegration time, but film quality was 
poor, particularly in terms of peeling off the film from the tray. Films were fragile and tore off 
upon peeling. 
Data was fitted into the model and results are depicted in Figure 1A. Film quality showed 
low validity. This might be explained as the influence of all the factors within film properties in 
various formulations is expected to show variations and the assessment of response might include 
some subjectivity of the criteria. Also, the qualitative nature of film quality that depends on 
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individual evaluation and hence subjectivity can result in error that jeopardized the validity of the 
model. Therefore, this response was excluded from the model and the model was refitted with 
three responses (disintegration time, content uniformity and thickness uniformity). For the three 
responses, model fitting as expressed in R2 that exceeded 90% mark for all the three responses, 
whereas, the prediction power (Q2) showed good prediction ability (0.89, 0.72 and 0.64 for 
disintegration time, content uniformity and thickness uniformity respectively) as they exceeded 
the threshold of 0.25 (Dahmash et al., 2018).  Further, the model was valid for the three responses, 
the highest was for thickness uniformity 0.80 and the lowest was for disintegration time 0.59. The 
three responses showed excellent reproducibility that exceeded 88% for all of them.  The wide 
variation in the response’s values for different formulations and the high degree of fitting of the 
model (Figure 1B) suggest that the responses (except for film quality) are strongly dependent on 
the selected independent factors.
Figure 1 [near here]
Further examination of the model validity once the response, film quality, was excluded, 
was done through several plots as can be seen in Figure 2. Figure 2A showed that the predicted 
versus observed response showed strong correlation with R2 exceeding 0.9 (0.99 for disintegration 
time, 0.93 for content uniformity and 0.94 for thickness uniformity). 
Figure 2 [near here]
Similarly, residual versus run order (Figure 2B) demonstrated the ideal random order 
indicating absence of trend and pattern according to run order (i.e., error was not built up with run 
order). Plotting Replicate index (Figure 2C) showed that all replicated runs were close to each 
other (i.e., less than 5% variations between them) and hence high reproducibility of the model. 
Page 16 of 38
Statistical analysis for testing the model validity is summarized in Table 5. A P value of 
less than 0.05 for the regression model suggests a statistically significant model for each response. 
The correlation coefficient (R2) for the three responses indicates good fit of the data (observed 
data) in the revised model. From the ANOVA analysis also, the P value due to lack of fit of more 
than 0.05 for all responses also, indicate valid model and that the errors are not due to lack of fit. 
The results indicate that the model is statistically significant. 
Table 5 [near here]
3.1.1 Regression model equations for all responses
Once the overall significance of the model factors was determined; the regression coefficients 
of the model terms were examined to identify the significant model terms for each response using 
the regression coefficients plots (Figure 3). The first seven coefficients represent the linear terms 
and reveal the effect of each individual factor. The other coefficients (bars) represent the 
interaction terms, which show the interactions (if any) among the factors. The length of the 
coefficient bar indicates the magnitude of the effect, while the confidence interval represents the 
noise (Dahmash et al., 2018). For example, the most significant factor affecting disintegration time 
was the polymer concentration. Increasing the polymer concentration resulted in an increase in the 
disintegration time. Increasing the polymer concentration resulted in thicker films, producing a 
more viscous outer layer upon hydration and hence took longer to disintegrate or dissolve (Irfan 
et al., 2016; Ouda et al., 2020; Saab and Mehanna, 2019). Polymer concentration and the polymer 
HPMC were the most significant interaction model terms that increased disintegration time. The 
quadratic term of polymer concentration also had high significance. 
Figure 3 [near here]
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The regression model of the three responses that included significant terms was built, 
where for each response, the quadratic model comprised of 21 terms. The model terms that showed 
significance (P value <0.05) were included into the regression equations (Equations 3-5, table 6).  
The value of each coefficient and the sign represented the impact and effect (negative or positive) 
respectively. For example, in thickness uniformity, the impact of HPMC polymer (X11) was the 
highest (2.18) and the negative sign indicates the reduction in RSD, which is favourable. The 
results also indicate that content uniformity of the films was significantly influenced by the linear 
models of HPMC polymer (X11), guar gum (X13) and polymer concentration (X2).  
Table 6 [near here]
3.1.2 The effect of independent variables (factors) on dependent variables (responses)
The effect of the linear model terms on film properties (Figure 4A) showed that the HPMC 
polymer produced films with lower disintegration time, excellent content uniformity and the 
lowest RSD in thickness uniformity. Although PEO produced films with excellent content 
uniformity, disintegration time was higher than that of HPMC and thickness uniformity was above 
the maximum allowed limit of 5%. Such results could be attributed to the use of high grade of 
PEO and which produced more viscous environment upon hydration when compared to HPMC 
and hence the increase in disintegration time. Although, guar gum containing films produced low 
disintegration time, it resulted in poor film properties (difficult to peel off the casting surface) and 
hence produced inconsistency in film thickness as can be seen from the high RSD values.   
Figure 4 [near here]
Polymer concentration had a detrimental effect on disintegration time of the films but better 
film thickness uniformity (Figure 4B). Higher polymer concentration as discussed earlier produced 
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more viscous solutions upon hydration and hence delayed dissolution and disintegration time 
particularly, in the absence of disintegrating agent. However, slight increase in solution viscosity 
resulted in easy spread of the solution on the casting surface and hence better film thickness 
uniformity. However, the results revealed that the polymer concentration did not affect content 
uniformity where the drug content was optimal. This could be attributed to high drug load of the 
film and the small range of polymer concentration used, as one of the aims of this study was 
polymer concentration optimisation. Our previous work (Ouda et al., 2020) with very high polymer 
concentration resulted in detrimental content uniformity due to difficulty in pouring the solution 
on the casting tray and huge variations in film thickness.  
The interaction between polymer type and concentration was the most significant on 
disintegration time and content uniformity as evident from the regression model (Eq.3 and 4) with 
coefficient factor of +6.59 for HPMC and - 7.12 for GG on disintegration time and +1.81 for 
HPMC on content uniformity. From Figure 4C, low polymer concentration produced films with 
low disintegration time for the three polymers, yet, the lowest was for HPMC. Overall, HPMC 
demonstrated the best film forming characteristic and good disintegration time. Similar results 
were reported by (Ouda et al., 2020). However, when the polymer concentration was further 
increased, films prepared from HPMC and PEO showed similar high disintegration profile while 
GG produced poor films that were hard to peel but lacked mechanical strength and hence 
disintegrated rapidly. However, the interaction effect on content uniformity was minimal with the 
most prevailing effect observed when HPMC was used. But, despite the change with polymer 
concentration it was within the targeted range. 
Equation 3 and 4 also showed significant interaction terms; polymer concentration (X2) 
and plasticizer type (X3) on disintegration time and content uniformity. The results in Figure 4D 
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suggest that at low polymer concentration, the plasticizer type has no effect. While, upon the 
increase in the polymer concentration, glycerine containing films demonstrate higher 
disintegration time when compared to sorbitol. Unfortunately, when high polymer concentration 
was used sorbitol produced a lot of bubbles that could not be removed upon sonication, which 
resulted in presences of air bubbles that resulted in faster disintegration time. Such films obtained 
low scores in terms of film quality. The effect of plasticizer on content uniformity was acceptable 
for both plasticizers. Despite a slight difference at low polymer concentration, the effect was trivial 
as the results were in the targeted range for both plasticizers. 
From equation 3 also, the disintegration time was reduced when HPMC was used as a 
polymer with glycerine, while it was increased when sorbitol was used. On the other hand, for 
PEO, the addition of plasticizer resulted in an increase in disintegration time.
The addition of plasticizers to films is necessary to decrease polymer intermolecular forces, 
enhance the mobility of the polymer chains, and the mechanical properties of the ODF. Both 
glycerine and sorbitol are hydrophilic, though, glycerine demonstrated better plasticity of produced 
films (Müller et al., 2008). However, in this study when the polymer concentration was high for 
HPMC and when PEO was used sorbitol produced high level of bubble and films produced 
demonstrated lower disintegration time upon hydration due to the presence of bubbles. (i.e., air 
voids and hence more porous films). The presence of bubbles produced films with bad appearance 
(not smooth and air bubbles could be seen after drying). 
Response surface plots that simulate the influence of independent factors on each response 
were generated by the software. The plots for disintegration time, content uniformity and thickness 
uniformity are presented in Figure 5. The plots provide uninterrupted visual assessment of the 
change in response surface upon the variation of independent variables from low to high values 
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individually and concurrently (AlHusban et al., 2010). From the plots, it was noted that the main 
effect of varying the polymer concentration when HPMC was used and the plasticizer 
concentration when glycerine was selected is on disintegration time. Lower polymer concentration 
was required to obtain low disintegration time (20-30 seconds), while plasticizer effect was trivial. 
However, at higher polymer concentration, higher plasticizer concertation was preferred for lower 
disintegration time. Such results can be explained by the effect of plasticizer on polymer 
interaction and higher hydrophilicity of the film.  Varying polymer and plasticizer concentration 
did not produce films outside the targeted range for content uniformity and /or thickness 
uniformity. 
Figure 5 [near here]
3.1.3 Setting optimal formulation parameters
Based on the results obtained from the response surface plot, optimal formulation parameters 
within the independent variables that reveal the ranges that could result in optimal responses (low 
disintegration time of less than 60 seconds, content uniformity within ±5% and RSD of lower than 
2%) are illustrated in Figure 6.  From the graph, the green area represents the design space with 
independent factors (polymer concentration and plasticizer concentration) that could result in 
desired responses for both disintegration time, content uniformity and thickness uniformity. The 
zones marked with light blue and marine blue represent areas where the factors meet the criteria 
for disintegration and content uniformity or disintegration alone respectively. Whereas the white 
zone represents the factors when none of the criteria is met. For example, within the operable space 
optimal film properties could be obtained at point A and point B. At point A, the polymer 
concentration was set at -0.08 (equivalent to 0.78% of HPMC) while plasticizer concentration set 
at -0.899017 (equivalent to 0.11% glycerine) which is expected to produce disintegration time of 
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36.2 seconds, content uniformity of 95.0934% and RSD 1.98%.  Another operable zone was 
obtained (point B) when polymer was 0.0366077 (equivalent to 0.82% HPMC) and plasticizer 
0.946721 (equivalent to 0.29% glycerine) to produce films with disintegration time is 29.49 
seconds, content uniformity 95.04% and thickness uniformity of 1.996%. Overall, optimal ODFs 
can be obtained with polymer HPMC concentration ranging from 0.83% to 1.1% and glycerine 
plasticizer concentration ranging from 0.11% to 0.3%.
Figure 6 [near here]
3.2 Characterization of optimal topiramate ODF formulation
Optimal formulation was selected based on the results of the DoE particularly N4 with 
medium polymer concentration (0.8%) and high glycerine concentration (0.3%). Lower plasticizer 
concentration resulted in films that were difficult to peel off the casting surface and it was not 
homogeneous. Resulting films were good in term of homogeneity and ease of removal from the 
casting surface. The formulation produced films with good physical properties particulaly in terms 
of consistency, transparency and easy peeling off the casting tray. Figure 7 shows the obtained 
film from formulation N4, where it clearly shows that the film as trasparent and homogeneous. 
This formulation was taken for further investigations.
Figure 7 [near here]
Dissolution profile was assessed and as can be seen from Figure 8, more than 98% of 
topiramate was released within the first 10 minutes. Such results suggest possible increase in onset 
time and hence enhancement of pharmacokinetic profile of topiramate.  
Figure 8 [near here]
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Thermal stability of the topiramate loaded ODF (N4) was assessed using TGA. The TGA 
analysis is employed to determine the amount and rate of change in the weight of a sample as a 
function of temperature. The results are used to determine moisture content, as well as thermal and 
oxidative stability of materials. Thermal stability of the films comprising 25 mg topiramate, 
HPMC, and glycerine was investigated and results as depicted in Figure 9 (A) showed the 
topiramate powder TGA profile with a mass loss of around 45% at around 180-200 °C, followed 
by a further loss of mass in excess of 20% in the range of 200-300 °C. This loss of mass continued 
till 750 °C, where only around 20% of the material was left. Similar results were reported by Sena 
et al. (Sena Jr et al., 2008).  Figure 9 (B) revealed that the film contained about 5% residual water 
that evaporated around 100 °C; this could be attributed to the presence of glycerine that has the 
ability to retain water. Such water retention property of glycerine is responsible to its property as 
a plasticizer (Liu et al., 2001). The second decomposition and loss of mass at around 100-120 °C 
could be attributed to glycerine (Crnkovic et al., 2012). The next loss of material / decomposition 
was observed at about 200 °C represents the decomposition of topiramate. Both topiramate and 
HPMC demonstrated thermal decomposition at around 350 °C (Ding et al., 2015). In summary the 
topiramate ODF demonstrated good thermal stability. 
Figure 9 [near here]
The next set of experiments were focused on investigating the change in crystallinity of the 
formulation and the effect of production processes on material properties. Figure 10 (A) showed 
the XRD patterns of  topiramate powder that demonstrated numerous characteristic sharp peaks, 
suggesting that the drug was present in a crystalline state with major characteristic diffraction 
peaks appearing at a diffraction angle of 2θ value of 11.93 º,15.15 º, 17.1º, 20 º, which is in line 
with published literature (Yang et al., 2014) . HPMC is a known amorphous material that showed 
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a broad “halo” pattern with few maxima. HPMC had two peaks at 10° and 22° 2θ (Storey and 
Ymén, 2011).  Using topiramate with HPMC resulted in XRD patterns for the film that revealed 
many characteristic high intensity peaks and relative intensities of topiramate that are presented in 
XRD confirming that the process of ODF production did not affect the crystallinity of the drug 
Figure 10 (B). 
Figure 10 [near here]
SEM images of the obtained topiramate containing film (N4) are depicted in Figure 11. It 
is clear from the SEM images that the surface is smooth and coalescent (A and B) and that HPMC 
particles coalesced into a smooth film. The crystalline active pharmaceutical ingredient 
(topiramate) particles were distributed throughout the film with few clusters of topiramate are seen 
at the centre
Figure 11 [near here]
Determining the mechanical properties of the ODFs is critical to its use. Tensile strength 
and elongation were measured. The tensile strength is calculated by the applied forces of break 
divided by the cross-sectional area of the film (Irfan et al., 2016). Good ODFs should have 
moderate tensile strength and high elongation. The elongation is a measure of plasticity, with 
results demonstrating more than 3% capability and good tensile strength that exceeded 22 MPa.  
Nevertheless, no specific limits are defined to ensure the appropriate mechanical properties of 
films (Irfan et al., 2016).  Table 7 lists the mechanical properties of the selected formulation (N4).
Table 7 [near here]
Overall, this study revealed that topiramate could successfully be loaded onto ODFs using 
HPMC as film forming polymer and glycerine as plasticizer, to produce doses of 25 mg/ film. 
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4. Conclusions
This work has successfully developed and validated orally dissolving films containing 25mg 
topiramate as a potential alternative dosage form for treatment of indicated epileptic disorders in 
children. The D-optimal multifactorial design of experiment applied in this study enabled the 
understanding of the effect of independent variables (polymer type, polymer concentration, 
plasticizer type and plasticizer concentration) on four responses. The analysis of variance revealed 
that all the independent variables had significant effect on three responses (disintegration time, 
content uniformity and thickness uniformity). The revised model showed high degree of reliability 
and enabled the identification of design space that produced ODF formulations with optimal 
properties. The optimized films contained hydroxypropyl methyl cellulose (HPMC) as hydrophilic 
film forming agent and glycerine as plasticizer. The developed film released 98% of topiramate 
within 10 mins and maintained the physicochemical stability of the drug as analysed using TGA, 
XRD and SEM. This study identified the type of polymer used as having the highest influence on 
the characteristics of the film produced. 
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 Tables:
Table 1: Summary of the Composition of Topiramate loaded ODFs Highlighting Polymer Type (HPMC, PEO or 
GG) and Concentration; Plasticizer type (Sorbitol or Glycerine) and concentrations.
Concentration [%w/v] per Batch Amount (mg) per ODF 2*3 (6cm2)] Based 
on Dry Weight
Range 
Polymer Plasticizer Topiramate Polymer Plasticizer Topiramate
Film Weight (mg))
-1 0.4 0.1 0.9 11.1 2.8 25.0 38.9
0 0.8 0.2 0.9 22.2 5.6 25.0 52.8
1 1.2 0.3 0.9 33.33 8.33 25.0 66.7
Table 2: List of factors and responses with their details that were employed in the DoE study.
Factor Abbr. Units Type Settings Precision
Polymer type Pol  Qualitative HPMC, PEO, GG  
Polymer concentration* PC % Quantitative -1 to 1 0.05
Plasticizer type Pla  Qualitative Glycerine, Sorbitol  
Plasticizer concentration** PLC  % Quantitative -1 to 1 0.05
Responses Abbr. Units Min Target Max
Disintegration time Dis Sec 5 20 60
Film Quality Fil % 0 80 100
Content uniformity Con % None 80 100
Thickness Uniformity RSD Thi % None 1 2
*Polymer concentration %w/v: -1 = 0.4%, 0= 0.8%, +1=1.2%
**Plasticizer concentration %w/v: -1= 0.1%, 0= 0.2%, +1= 0.3%
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Table 3: The D-optimal design worksheet with factors, responses the total number of runs as well as the run order 





























































1 N1 6 Incl
HPM
C
-1 Gly 0 10
0 10 10 10 10
40 90.3 0.061 5.8






20 20 20 20 20
100 94.3 0.074 1.03






10 20 20 10 20
80 95.6 0.068 2.2






20 20 20 20 20
100 94.7 0.066 1.95
5 N5 13 Incl PEO 1 Gly -1 90 10 20 20 10 20 80 93.6 0.078 3.6
6 N6 7 Incl PEO 1 Gly 1 86 20 20 20 20 20 100 94.6 0.079 2.5
7 N7 17 Incl PEO -1 Gly 0 35 10 20 10 10 10 60 93.9 0.071 5.67
8 N8 12 Incl GG -1 Gly -1 27 0 10 0 0 0 10 82.6 0.070 6.8




20 Incl GG 1
Gly
0 60
0 20 10 0 10







-1 Sor -1 21
10 10 0 10 10







1 Sor -1 80
10 20 20 20 10







-1 Sor 1 20
10 20 10 0 0
40 98.6 0.063 2.87







1 Sor 1 77
20 20 10 10 0







0 Sor 0 44
20 20 20 10 10




4 Incl PEO -1 Sor -1 26
0 10 10 0 0




2 Incl PEO -1 Sor 1 18
10 10 10 10 0




22 Incl PEO 1 Sor 0 63
10 20 10 10 10




1 Incl GG 1 Sor -1 50
10 20 10 0 0




8 Incl GG 1 Sor 1 47
10 20 10 0 0




18 Incl GG -1 Sor 0 30
0 10 0 0 0




14 Incl GG 0 Sor 0 35
0 20 0 0 0




3 Incl GG 0 Sor 0 35
0 20 0 0 0




5 Incl GG 0 Sor 0 32
0 20 0 0 0
20 101.5 0.068 7.45
Table 4: Scoring Criteria for ODF highlighting the distribution of scores. 
Score (%)                          Scoring Scheme 
Elements Poo (0%) Average (10%) Good (20%)
Film flexibility (endurance > 30 times) <20 times 20-30 >30 times
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Spreadability upon pouring onto the casting tray Does not spread





Very sticky that 
could not be 
handled easily
Some stickiness 
but could be 
handled 
Not sticky
Easy to peel off the casting tray
Could not be 
peeled off













Table 5: Summary of the ANOVA results for the three responses to test model validity, where P is the probability 




Lack of Fit 0.195
Content Uniformity
Regression 0.000 0.926
Lack of Fit 0.411
Thickness Uniformity
Regression 0.000 0.916
Lack of Fit 0.452
Table 6: Regression equations for the responses (dependent variable) highlighting the effect of all significant model 
terms on each response. 
Y1= 39.01 + 2.44*X11 - 2.59*X13 + 19.57*X2 + 1.73*X31 - 1.73*X32 + 5.48*X2*X2 + 6.59*X11*X2 - 7.12*X13*X2 -
6.14 X11*X31 + 6.14*X11*X32 + 6.27 *X12*X31 - 6.27*X12*X32 + 3.28*X2*X31 - 3.28*X2*X32 ----------(Eq 3)
Y2= 102.06+ 2.01 X11 - 3.33* X31 + 3.33 X32 - 5.15* X2*X2 - 2.61 * X4*X4 + 1.81 X11*X2+ 2.19 X12*X31 -2.19 * 
X12*X32 + 3.17 *X2*X31 -3.17* X2*X32 --------------------------------------------------------------------------(Eq 4)
Y3= 5.47 - 2.18 *X11 + 1.95*X13 – 0.63 *X2 - 0.91 X2*X31 + 0.91* X2*X32--------------------------------------- (Eq 5)
Y1 Disintegration time 
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Y2 Content uniformity 
Y3 Thickness uniformity 
X1 Polymer type X11 HPMC X12 PEO X13 GG
X2 Polymer concentration 
X3 Plasticizer type X31 Glycerine X32 Sorbitol
X4 Plasticizer concentration 
Table 7: Mechanical Properties of topiramate loaded ODF (N4) 3 × 2 cm2 (Mean ± SD, n = 3)
Property Mean SD
Tensile strength (MPa) 22.53 4.54
% Elongation 1.81 0.34
Energy to break (J) 0.0073 0.0006
Thickness (mm) 0.066 0.0013
Width (mm) 19.87 0.63
Figures:
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Figure 1: Summary of fit for all responses highlighting the degree of fit (R2), prediction power (Q2) model 
validity and reproducibility. Total number of runs 24. (A) The model included film quality which 
demonstrated poor validity, (B) Summary of Fit upon the exclusion of film quality as a response and 
revision of all model terms. 
Figure 2: (A) Observed versus predicted for all responses highlightimg the significance of the model. (B) 
Residual versus run order of all responses. (C) Replicate index for all responses, highlighting the closeness 
of the centre points (replicates).
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Figure 3: Regression coefficient plot of model terms for: (A) disintegration time in seconds (B) content uniformity 
% and (C) thickness uniformity %. The length of the bar indicates the magnitude of the effect of each model term, 
whereas the direction represents negative or positive effect. Significant effect is determined when the confidence 
intervals do not cross zero.
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Figure 4: Main effect plots of (A) the polymer type on the three responses, when other factors maintained at their 
middle values. Note the D-optimal design has no centre points and hence were not displayed. (B) The polymer 
concentration on disintegration time and film thickness uniformity when other factors maintained at their middle 
values. Note the D-optimal design has no centre points and hence were not displayed. (C) Interaction effect plot of 
polymer type with increasing polymer concentration on disintegration time and content uniformity while the other 
factors were maintained at their middle values. (D) Interaction effect plot of polymer concentration with plasticizer 
type on disintegration time and content uniformity while the other factors were maintained at their middle values.
Figure 3: Response Surface Model (RSM) plot showing the effect of varying the polymer concentration (HPMC) 
and plasticizer concentration (Glycerine) on the three responses (disintegration time, content uniformity and 
thickness uniformity). 
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Figure 4: Sweet spot for optimal ranges of the independent variables (polymer concentration and plasticizer 
concentration) for the desired profile of ODFs (disintegration time, content uniformity and thickness uniformity) while 
HPMC and Glycerine were selected as polymer and plasticizer respectively. 
Figure 57: Topiramate loaded ODF (N4) made from HPMC, topiramate and glycerine size 2x3 cm.
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Figure8: Percentage released over time of topiramate loaded ODF (N4) made from HPMC, topiramate and glycerine 
size 2x3 cm2 (mean ± SD, n=3).
Figure9: TGA profile of (A) topiramate powder, (B) ODF (N4) composed of 25 mg topiramate, HPMC and 
glycerine, all obtained at a heating rate of 10°C/min under N2 atmosphere.
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Figure 6: Typical XRD patterns of (A) topiramate pure powder, (B) ODF N4 topiramate loaded 25 mg  
collected on D8 Phaser diffractometer.
                 
Figure11: SEM micrographs of (A) topiramate containing ODF- N4 at 50× magnification showing the surface of 
the film, (B) N4 at 100× magnification, (C) N4  at 500× magnification and (D) N4 at 1000× magnification. The 
while patches in C and D represents clusters of Crystalline topiramate. 
